Risk Assessment and Refined Management of Blood Collection and Supply during the COVID-19 Epidemic

Since the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to spread worldwide and has become a major global public health threat. SARS-CoV-2 has the characteristics of a long incubation period and asymptomatic infection, which are undoubtedly major challenges to blood transfusion safety. Although no research has suggested that there is a risk of SARS-CoV-2 transmission through blood transfusion, the safe use of clinical blood during the epidemic is a serious problem faced by blood collection and supply institutions. Herein, we elaborate on the management of blood collection and supply during the coronavirus disease 2019 (COVID-19) pandemic from aspects such as blood inventory management, clinical blood use, and reducing the risk of transmission of SARS-CoV-2 via blood transfusion. Blood service departments should adopt flexible policies to ensure that blood collection networks can meet clinical needs, while at the same time protecting staff and blood donors, maintaining blood safety, and reducing blood risks during the epidemic.

Smart multi-functional aggregates reoxygenate tumor microenvironment through a two-pronged strategy to revitalize cancer immunotherapy

PD-1/PD-L1 inhibitors have emerged as standard treatments for advanced solid tumors;however,challenges such as a low overall response rate and systemic side effects impede their implementation.Hypoxia drives the remodeling of the tumor microenvironment,which is a leading reason for the failure of immunotherapies.Despite some reported strategies to alleviate hypoxia,their individual limitations constrain further improvements.Herein,a novel two-pronged strategy is pre-sented to efficiently address hypoxia by simultaneously adopting atovaquone(ATO,inhibiting oxygen consumption)and oxyhemoglobin(HbO2,directly supplement-ing oxygen)within a multifunctional aggregate termed NPs-aPD-1/HbO2/ATO.In addition to eliminating hypoxia with these two components,this smart aggre-gate also includes albumin and an ROS-responsive cross-linker as a controlled release scaffold,along with PD-1 antibody(aPD-1)for immunotherapy.Intriguingly,NPs-aPD-1/HbO2/ATO demonstrates exceptional tumor targeting in vivo,exhibit-ing≈4.2 fold higher accumulation in tumors than in the liver.Consequently,this aggregate not only effectively mitigates hypoxia and significantly assists aPD-1 immunotherapy but also simultaneously resolves the targeting and systemic toxicity issues associated with individual administration of each component.This study pro-poses substantial implications for drug-targeted delivery,addressing tumor hypoxia and advancing immunotherapy,providing valuable insights for advancing cancer treatment strategies.